Nature Communications (Nov 2021)
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
- Amy S. Clark,
- Christina Yau,
- Denise M. Wolf,
- Emanuel F. Petricoin,
- Laura J. van ‘t Veer,
- Douglas Yee,
- Stacy L. Moulder,
- Anne M. Wallace,
- A. Jo Chien,
- Claudine Isaacs,
- Judy C. Boughey,
- Kathy S. Albain,
- Kathleen Kemmer,
- Barbara B. Haley,
- Hyo S. Han,
- Andres Forero-Torres,
- Anthony Elias,
- Julie E. Lang,
- Erin D. Ellis,
- Rachel Yung,
- Debu Tripathy,
- Rita Nanda,
- Julia D. Wulfkuhle,
- Lamorna Brown-Swigart,
- Rosa I. Gallagher,
- Teresa Helsten,
- Erin Roesch,
- Cheryl A. Ewing,
- Michael Alvarado,
- Erin P. Crane,
- Meredith Buxton,
- Julia L. Clennell,
- Melissa Paoloni,
- Smita M. Asare,
- Amy Wilson,
- Gillian L. Hirst,
- Ruby Singhrao,
- Katherine Steeg,
- Adam Asare,
- Jeffrey B. Matthews,
- Scott Berry,
- Ashish Sanil,
- Michelle Melisko,
- Jane Perlmutter,
- Hope S. Rugo,
- Richard B. Schwab,
- W. Fraser Symmans,
- Nola M. Hylton,
- Donald A. Berry,
- Laura J. Esserman,
- Angela M. DeMichele
Affiliations
- Amy S. Clark
- University of Pennsylvania
- Christina Yau
- University of California San Francisco
- Denise M. Wolf
- University of California San Francisco
- Emanuel F. Petricoin
- George Mason University
- Laura J. van ‘t Veer
- University of California San Francisco
- Douglas Yee
- University of Minnesota
- Stacy L. Moulder
- MD Anderson Cancer Center
- Anne M. Wallace
- University of California San Diego
- A. Jo Chien
- University of California San Francisco
- Claudine Isaacs
- Georgetown University
- Judy C. Boughey
- Mayo Clinic
- Kathy S. Albain
- Loyola University
- Kathleen Kemmer
- Oregon Health & Science University
- Barbara B. Haley
- University of Texas Southwestern
- Hyo S. Han
- Moffitt Cancer Center
- Andres Forero-Torres
- University of Alabama Birmingham
- Anthony Elias
- University of Colorado Denver
- Julie E. Lang
- University of Southern California
- Erin D. Ellis
- Swedish Cancer Institute
- Rachel Yung
- University of Washington
- Debu Tripathy
- MD Anderson Cancer Center
- Rita Nanda
- University of Chicago
- Julia D. Wulfkuhle
- MD Anderson Cancer Center
- Lamorna Brown-Swigart
- University of California San Francisco
- Rosa I. Gallagher
- MD Anderson Cancer Center
- Teresa Helsten
- University of California San Diego
- Erin Roesch
- University of California San Diego
- Cheryl A. Ewing
- University of California San Francisco
- Michael Alvarado
- University of California San Francisco
- Erin P. Crane
- Georgetown University
- Meredith Buxton
- Berry Consultants, LLC
- Julia L. Clennell
- Berry Consultants, LLC
- Melissa Paoloni
- Berry Consultants, LLC
- Smita M. Asare
- University of California San Francisco
- Amy Wilson
- University of California San Francisco
- Gillian L. Hirst
- University of California San Francisco
- Ruby Singhrao
- University of California San Francisco
- Katherine Steeg
- University of California San Francisco
- Adam Asare
- University of California San Francisco
- Jeffrey B. Matthews
- University of California San Francisco
- Scott Berry
- Berry Consultants, LLC
- Ashish Sanil
- Berry Consultants, LLC
- Michelle Melisko
- University of California San Francisco
- Jane Perlmutter
- Gemini Group
- Hope S. Rugo
- University of California San Francisco
- Richard B. Schwab
- University of California San Diego
- W. Fraser Symmans
- MD Anderson Cancer Center
- Nola M. Hylton
- University of California San Francisco
- Donald A. Berry
- Berry Consultants, LLC
- Laura J. Esserman
- University of California San Francisco
- Angela M. DeMichele
- University of Pennsylvania
- DOI
- https://doi.org/10.1038/s41467-021-26019-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pertuzumab) in the context of the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence.
